Perioperative pharmacological management of pulmonary hypertensive crisis during congenital heart surgery

Pulmonary Circulation

Volumn 4, Issue 1, 2014, Pages 10-24

  Brunner, Nathan ^a   de Jesus Perez, Vinicio A ^a   Richter, Alice ^a   Haddad, François ^a   Denault, André ^b   Rojas, Vanessa ^a   Yuan, Ke ^a   Orcholski, Mark ^a   Liao, Xiaobo ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONTREAL HEART INSTITUTE   (Canada)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Congenital heart diseases; Perioperative pharmacological therapies; Pulmonary arterial hypertension; Pulmonary hypertensive crisis

Indexed keywords

EID: 85026336278     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/674885     Document Type: Review

References (133)

1. Galie N, Manes A, Palazzini M, Negro L, Marinelli A, Gambetti S, Mariucci E, Donti A, Branzi A, Picchio FM. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs 2008;68(8):1049-1066.
2. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53(17):1573-1619.
3. Hawkins A, Tulloh R. Treatment of pediatric pulmonary hypertension. Vasc Health Risk Manag 2009;5(2):509-524.
4. Schlingmann TR, Thiagarajan RR, Gauvreau K, Lofgren KC, Zaplin M, Connor JA, del Nido PJ, Lock JE, Jenkins KJ. Cardiac medical conditions have become the leading cause of death in children with heart disease. Congenit Heart Dis 2012;7(6):551-558.
5. Lindberg L, Olsson AK, Jogi P, Jonmarker C. How common is severe pulmonary hypertension after pediatric cardiac surgery? J Thorac Cardiovasc Surg 2002;123(6):1155-1163.
6. Bando K, Turrentine MW, Sharp TG, Sekine Y, Aufiero TX, Sun K, Sekine E, Brown JW. Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management. J Thorac Cardiovasc Surg 1996;112(6):1600-1609.
7. Antoniou T, Koletsis EN, Prokakis C, Rellia P, Thanop-oulos A, Theodoraki K, Zarkalis D, Sfyrakis P. Hemody-namic effects of combination therapy with inhaled nitric oxide and iloprost in patients with pulmonary hypertension and right ventricular dysfunction after high-risk cardiac surgery. J Cardiothorac Vasc Anesth 2013;27(3):459-466.
8. Adatia I, Beghetti M. Early postoperative care of patients with pulmonary hypertension associated with congenital cardiac disease. Cardiol Young 2009;19(4):315-319.
9. Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 2007;35(9): 2037-2050.
10. Prakanrattana U, Suksompong S, Sriyoschati S, Pornvila-wan S. Anesthesia for arterial switch operation in simple transposition ofthe great arteries: experience at Siriraj Hospital. J Med Assoc Thail 2002;85(suppl 3):S815-S823.
11. Vizza CD, Rocca GD, Roma AD, Iacoboni C, Pierconti F, Venuta F, Rendina E, Schmid G, Pietropaoli P, Fedele F. Acute hemodynamic effects of inhaled nitric oxide, do-butamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. Crit Care 2001;5(6):355-361.
12. Tritapepe L, Voci P, Cogliati AA, Pasotti E, Papalia U, Menichetti A. Successful weaning from cardiopulmonary bypass with central venous prostaglandin E1 and left atrial norepinephrine infusion in patients with acute pulmonary hypertension. Crit Care Med 1999; 27(10):2180-2183.
13. Kojima T, Nishisako R, Sato H. A patient with possible TRALI who developed pulmonary hypertensive crisis and acute pulmonary edema during cardiac surgery. J Anesth 2012;26(3):460-463.
14. Roberts DH, Lepore JJ, Maroo A, Semigran MJ, Ginns LC. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest 2001;120(5):1547-1555.
15. Checchia PA, Bronicki RA, Goldstein B. Review of inhaled nitric oxide in the pediatric cardiac surgery setting. Pediatr Cardiol 2012;33(4):493-505.
16. Umenai T, Shime N, Hashimoto S. Hyperventilation versus standard ventilation for infants in postoperative care for congenital heart defects with pulmonary hypertension. J Anesth 2009;23(1):80-86.
17. Carvalho CR, Barbas CS, Medeiros DM, Magaldi RB, Lorenzi Filho G, Kairalla RA, Deheinzelin D, et al. Temporal hemodynamic effects of permissive hypercapnia associated with ideal PEEP in ARDS. Am J Respir Crit Care Med 1997;156(5):1458-1466.
18. Viitanen A, Salmenpera M, Heinonen J. Right ventricular response to hypercarbia after cardiac surgery. Anesthesiol-ogy 1990;73(3):393-400.
19. Balanos GM, Talbot NP, Dorrington KL, Robbins PA. Human pulmonary vascular response to 4 h of hypercapnia and hypocapnia measured using Doppler echocardiography. J Appl Physiol 2003;94(4):1543-1551.
20. Beghetti M, Habre W, Friedli B, Berner M. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br Heart J 1995;73(1):65-68.
21. Miller OI, Tang SF, Keech A, Pigott NB, Beller E, Celermajer DS. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised doubleblind study. Lancet 2000;356(9240):1464-1469.
22. Journois D, Baufreton C, Mauriat P, Pouard P, Vouhe P, Safran D. Effects of inhaled nitric oxide administration on early postoperative mortality in patients operated for correction of atrioventricular canal defects. Chest 2005;128 (5):3537-3544.
23. Day RW, Hawkins JA, McGough EC, Crezee KL, Orsmond GS. Randomized controlled study of inhaled nitric oxide after operation for congenital heart disease. Ann Thorac Surg 2000;69(6):1907-1913.
24. Bizzarro M, Gross I. Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease. Cochrane Database Syst Rev 2005(4):CD005055.
25. Macrae DJ, Field D, Mercier JC, Moller J, Stiris T, Biban P, Cornick P, et al. Inhaled nitric oxide therapy in neonates and children: reaching a European consensus. Intensive Care Med 2004;30(3):372-380.
26. Germann P, Braschi A, Della Rocca G, Dinh-Xuan AT, Falke K, Frostell C, Gustafsson LE, et al. Inhaled nitric oxide therapy in adults: European expert recommendations. Intensive Care Med 2005;31(8):1029-1041.
27. Sim JY. Nitric oxide and pulmonary hypertension. Korean J Anesthesiol 2010;58(1):4-14.
28. Napoli C, Loscalzo J. Nitric oxide and other novel therapies for pulmonary hypertension. J Cardiovasc Pharmacol Ther 2004;9(1):1-8.
29. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 2006;174(9):1042-1047.
30. Mossad EB. Pro: Intraoperative use ofnitric oxide for treatment of pulmonary hypertension in patients with congenital heart disease is effective. J Cardiothorac Vasc Anesth 2001; 15(2):259-262.
31. Miller OI, Tang SF, Keech A, Celermajer DS. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 1995; 346(8966):51-52.
32. Knoderer CA, Ebenroth ES, Brown JW. Chronic outpatient sildenafil therapy for pulmonary hypertension in a child after cardiac surgery. Pediatr Cardiol 2005;26(6):859-861.
33. Loukanov T, Bucsenez D, Springer W, Sebening C, Rauch H, Roesch E, Karck M, Gorenflo M. Comparison of inhaled nitric oxide with aerosolized iloprost for treatment of pulmonary hypertension in children after cardiopulmonary bypass surgery. Clin Res Cardiol 2011; 100(7):595-602.
34. Palma G, Giordano R, Russolillo V, Cioffi S, Palumbo S, Mucerino M, Poli V, Vosa C. Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery. Tex Heart Inst J 2011;38(3):238-242.
35. Coceani F, Olley PM, Lock JE. Prostaglandins, ductus arteriosus, pulmonary circulation: current concepts and clinical potential. Eur J Clin Pharmacol 1980;18(1):75-81.
36. Bush A, Busst CM, Shinebourne EA. The use of oxygen and prostacyclin as pulmonary vasodilators in congenital heart disease. Int J Cardiol 1985;9(3):267-274.
37. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacy-clin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99(14):1858-1865.
38. Lang P, Freed MD, Bierman FZ, Norwood WI Jr., Nadas AS. Use of prostaglandin E1 in infants with d-transposition of the great arteries and intact ventricular septum. Am J Cardiol 1979;44(1):76-81.
39. Masutani S, Seki M, Taketazu M, Senzaki H. Successful management of the persistent pulmonary hypertension of the newborn with transposition of the great arteries by restricted patency of the ductus arteriosus: a simple and rational novel strategy. Pediatr Cardiol 2009;30(7):1003-1005.
40. Dong MF, Ma ZS, Ma SJ, Chai SD, Tang PZ, Yao DK, Wang L. Effect of prostaglandin E1 on pulmonary arterial hypertension following corrective surgery for congenital heart disease. J Cardiovasc Pharmacol Ther 2012;17(3):303-307.
41. Kermode J, Butt W, Shann F. Comparison between pros-taglandin E1 and epoprostenol (prostacyclin) in infants after heart surgery. Br Heart J 1991;66(2):175-178.
42. Della Rocca G, Coccia C, Pompei L, Costa MG, Di Marco P, Pietropaoli P. Inhaled aerosolized prostaglandin E1, pulmonary hemodynamics, and oxygenation during lung transplantation. Minerva Anestesiol 2008;74(11):627-633.
43. Gupta V, Ahsan F. Inhalational therapy for pulmonary arterial hypertension: current status and future prospects. Crit Rev Ther Drug Carrier Syst 2010;27(4):313-370.
44. Gupta V, Ahsan F. Influence of PEI as a core modifying agent on PLGA microspheres of PGE1, a pulmonary selective vasodilator. Int J Pharm 2011;413(1 2):51-62.
45. Fernandes SM, Newburger JW, Lang P, Pearson DD, Feinstein JA, Gauvreau K, Landzberg MJ. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 2003;91(5): 632-635.
46. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106(12):1477-1482.
47. Yamauchi H, Yamaki S, Fujii M, Iwaki H, Tanaka S. Reduction in recalcitrant pulmonary hypertension after operation for atrial septal defect. Ann Thorac Surg 2001;72 (3):905-907.
48. Frost AE, Quinones MA, Zoghbi WA, Noon GP. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J Heart Lung Transplant 2005;24(4): 501-503.
49. Haraldsson A, Kieler-Jensen N, Ricksten SE. Inhaled pros-tacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. J Cardiothorac Vasc Anesth 1996; 10(7):864-868.
50. De Wet CJ, Affleck DG, Jacobsohn E, Avidan MS, Tymkew H, Hill LL, Zanaboni PB, Moazami N, Smith JR. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 2004;127(4):1058-1067.
51. Hache M, Denault A, Belisle S, Robitaille D, Couture P, Sheridan P, Pellerin M, et al. Inhaled epoprostenol (pros-tacyclin) and pulmonary hypertension before cardiac surgery. J Thorac Cardiovasc Surg 2003;125(3):642-649.
52. Brown AT, Gillespie JV, Miquel-Verges F, Holmes K, Ravekes W, Spevak P, Brady K, et al. Inhaled epoprostenol therapy for pulmonary hypertension: improves oxygenation index more consistently in neonates than in older children. Pulm Circ 2012;2(1):61-66.
53. Dahlem P, van Aalderen WM, de Neef M, Dijkgraaf MG, Bos AP. Randomized controlled trial of aerosolized pros-tacyclin therapy in children with acute lung injury. Crit Care Med 2004;32(4):1055-1060.
54. Zwissler B, Rank N, Jaenicke U, Schurle B, Welte M, Reichart B, Netz H, Messmer K, Peter K. Selective pulmonary vasodilation by inhaled prostacyclin in a newborn with congenital heart disease and cardiopulmonary bypass. An-esthesiology 1995;82(6):1512-1516.
55. Kovach J, Ibsen L, Womack M, Steusse D, Law YM. Treatment of refractory pulmonary arterial hypertension with inhaled epoprostenol in an infant with congenital heart disease. Congenit Heart Dis 2007;2(3):194-198.
56. Carroll CL, Backer CL, Mavroudis C, Cook K, Goodman DM. Inhaled prostacyclin following surgical repair of congenital heart disease: a pilot study. J Card Surg 2005;20 (5):436-439.
57. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Phar-macokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004;44(2):209-214.
58. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800-804.
59. Kallen AJ, Lederman E, Balaji A, Trevino I, Petersen EE, Shoulson R, Saiman L, et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 2008;29(4):342-349.
60. Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S, Gall H, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006;48(8):1672-1681.
61. Mirza S, Foley RJ. Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension. Clin Med Insights Circ Respir Pulm Med 2012; 6:41-50.
62. Bourge RC, Tapson VF, Safdar Z, Benza RL, Channick RN, Rosenzweig EB, Shapiro S, et al. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. Cardiovasc Ther 2013;31(1):38-44.
63. de Jesus Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, Jain M, et al. Safety and efficacy of transition from systemic prostanoids to inhaled tre-prostinil in pulmonary arterial hypertension. Am J Cardiol 2012;110(10):1546-1550.
64. Krishnan U, Takatsuki S, Ivy DD, Kerstein J, Calderbank M, Coleman E, Rosenzweig EB. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. Am J Cardiol 2012;110 (11):1704-1709.
65. Olschewski H, Rohde B, Behr J, Ewert R, Gessler T, Ghofrani HA, Schmehl T. Pharmacodynamics and phar-macokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003;124(4):1294-1304.
66. Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, Friedli B, Beghetti M. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 2001; 103(4):544-548.
67. Limsuwan A, Wanitkul S, Khosithset A, Attanavanich S, Samankatiwat P. Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. Int J Cardiol 2008;129(3):333-338.
68. Kirbas A, Yalcin Y, Tanrikulu N, Gurer O, Isik O. Comparison of inhaled nitric oxide and aerosolized iloprost in pulmonary hypertension in children with congenital heart surgery. Cardiol J 2012;19(4):387-394.
69. Yu J, Taylor L, Wilson J, Comhair S, Erzurum S, Polgar P. Altered expression and signal transduction of endothelin-1 receptors in heritable and idiopathic pulmonary arterial hypertension. J Cell Physiol 2013;228(2):322-329.
70. Dhillon S, Keating GM. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension. Am J Cardiovasc Drugs 2009;9(5):331-350.
71. Gatzoulis MA, Alonso-Gonzalez R, Beghetti M. Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease. Eur Respir Rev 2009;18 (113):154-161.
72. Schulze-Neick I, Gilbert N, Ewert R, Witt C, Gruenig E, Enke B, Borst MM, Lange PE, Hoeper MM. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study ofbosentan therapy. Am Heart J 2005;150(4):716.
73. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Heart 2005;91(11):1447-1452.
74. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114(1):48-54.
75. Williams R, Houser L, Miner P, Aboulhosn J. Efficacy and safety of bosentan in adults with simple and complex Eisen-menger's syndrome. Congenit Heart Dis 2012;7(1):12-15.
76. Eicken A, Balling G, Gildein HP, Genz T, Kaemmerer H, Hess J. Transcatheter closure of a non-restrictive patent ductus arteriosus with an Amplatzer muscular ventricular septal defect occluder. Int J Cardiol 2007;117(1):e40-e42.
77. Hoetzenecker K, Ankersmit HJ, Bonderman D, Hoetzenecker W, Seitelberger R, Klepetko W, Lang IM. Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: a case report. J Thorac Cardiovasc Surg 2009; 37(3):760-761.
78. Ovaert C, Thijs D, Dewolf D, Ottenkamp J, Dessy H, Moons P, Gewillig M, Mertens L. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young 2009;19(4):331-339.
79. Hirono K, Yoshimura N, Taguchi M, Watanabe K, Nakamura T, Ichida F, Miyawaki T. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery. J Thorac Cardiovasc Surg 2010;140(2):346-351.
80. Schuuring MJ, Boekholdt SM, Windhausen A, Bouma BJ, Groenink M, Keijzers M, De Winter RJ, Koolbergen DR, Blom NA, Mulder BJ. Advanced therapy for pulmonary arterial hypertension due to congenital heart disease: a clinical perspective in a new therapeutic era. Neth Heart J 2011; 19(12):509-513.
81. Beghetti M, Tissot C. Pulmonary arterial hypertension and congenital heart disease: targeted therapies and operability. J Thorac Cardiovasc Surg 2009;138(3):785-786.
82. Hoetzenecker K, Ankersmit HJ, Lang IM. Reply to the editor. J Thorac Cardiovasc Surg 2009;138(3):786.
83. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010-3019.
84. Ivy D. Advances in pediatric pulmonary arterial hypertension. Curr Opin Cardiol 2012;27(2):70-81.
85. Takatsuki S, Rosenzweig EB, Zuckerman W, Brady D, Calderbank M, Ivy DD. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol 2013;48 (1):27-34.
86. Cheng JW. Ambrisentan for the management of pulmonary arterial hypertension. Clin Ther 2008;30(5):825-833.
87. Majure DT, Greco T, Greco M, Ponschab M, Biondi-Zoccai G, Zangrillo A, Landoni G. Meta-analysis of randomized trials of effect of milrinone on mortality in cardiac surgery: an update. J Cardiothorac Vasc Anesth 2013;27(2): 220-229.
88. Lamarche Y, Malo O, Thorin E, Denault A, Carrier M, Roy J, Perrault LP. Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopul-monarybypass. J Thorac Cardiovasc Surg 2005;130(1):83-92.
89. Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, Bailey JM, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003;107(7):996-1002.
90. Lechner E, Hofer A, Leitner-Peneder G, Freynschlag R, Mair R, Weinzettel R, Rehak P, Gombotz H. Levosi-mendan versus milrinone in neonates and infants after corrective open-heart surgery: a pilot study. Pediatr Crit Care Med 2012;13(5):542-548.
91. Momeni M, Rubay J, Matta A, Rennotte MT, Veyckemans F, Poncelet AJ, Clement de Clety S, Anslot C, Joomye R, Detaille T. Levosimendan in congenital cardiac surgery: a randomized, double-blind clinical trial. J Cardiothorac Vasc Anesth 2011;25(3):419-424.
92. Haraldsson A, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 2001;93(6):1439-1445.
93. Carev M, Bulat C, Karanović N, Lojpur M, Jerčić A, Nenadić D, Marović Z, Husedžinović I, Letica D. Combined usage of inhaled and intravenous milrinone in pulmonary hypertension after heart valve surgery. Coll Antropol 2010;34(3):1113-1117.
94. Katz SL, Adatia I, Louca E, Leung K, Humpl T, Reyes JT, Coates AL. Nebulized therapies for childhood pulmonary hypertension: an in vitro model. Pediatr Pulmonol 2006; 41(7):666-673.
95. Lamarche Y, Perrault LP, Maltais S, Tetreault K, Lambert J, Denault AY. Preliminary experience with inhaled milri-none in cardiac surgery. Eur J Cardiothorac Surg 2007;31(6): 1081-1087.
96. Zhang J, Chen F, Zhao X, Aoyama A, Okamoto T, Fujinaga T, Shoji T, et al. Nebulized phosphodiesterase III inhibitor during warm ischemia attenuates pulmonary ischemia-reperfusion injury. J Heart Lung Transplant 2009; 28(1):79-84.
97. Singh R, Choudhury M, Saxena A, Kapoor PM, Juneja R, Kiran U. Inhaled nitroglycerin versus inhaled milrinone in children with congenital heart disease suffering from pulmonary artery hypertension. J Cardiothorac Vasc Anesth 2010;24(5):797-801.
98. Mukhopadhyay S, Sharma M, Ramakrishnan S, Yusuf J, Gupta MD, Bhamri N, Trehan V, Tyagi S. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 2006;114(17):1807-1810.
99. Chau EM, Fan KY, Chow WH. Effects of chronic silden-afil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007; 120(3):301-305.
100. D'Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, Correra A, Scognamiglio G, Russo MG, Calabro R. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol 2012; 155(3):378-382.
101. Trachte AL, Lobato EB, Urdaneta F, Hess PJ, Klodell CT, Martin TD, Staples ED, Beaver TM. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg 2005;79(1):194-197.
102. Klodell CT Jr., Morey TE, Lobato EB, Aranda JM Jr., Staples ED, Schofield RS, Hess PJ, Martin TD, Beaver TM. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg 2007; 83(1):68-71.
103. Zakliczynski M, Maruszewski M, Pyka L, Trybunia D, Nadziakiewicz P, Przybylski R, Zembala M. Effectiveness and safety of treatment with sildenafil for secondary pulmonary hypertension in heart transplant candidates. Transplant Proc 2007;39(9):2856-2858.
104. Shim JK, Choi YS, Oh YJ, Kim DH, Hong YW, Kwak YL. Effect of oral sildenafil citrate on intraoperative hemody-namics in patients with pulmonary hypertension undergoing valvular heart surgery. J Thorac Cardiovasc Surg 2006;132(6):1420-1425.
105. Atz AM, Lefler AK, Fairbrother DL, Uber WE, Bradley SM. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 2002;124(3):628-629.
106. Nemoto S, Sasaki T, Ozawa H, Katsumata T, Kishi K, Okumura K, Mori Y, Umegaki O. Oral sildenafil for persistent pulmonary hypertension early after congenital cardiac surgery in children. Eur J Cardiothorac Surg 2010;38 (1):71-77.
107. Lee JE, Hillier SC, Knoderer CA. Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med 2008;23(5):329-334.
108. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009;154(3): 379-384e2.
109. Lammers AE, Haworth SG, Pierce CM. Intravenous sildenafil as an effective treatment of pulmonary hypertensive crises during acute intestinal malabsorption. Cardiol Young 2006;16(1):84-86.
110. Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med 2003;29(11):1996-2003.
111. Schulze-Neick I, Hartenstein P, Li J, Stiller B, Nagdyman N, Hübler M, Butrous G, Petros A, Lange P, Redington AN. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 2003; 108(10 suppl):II-167-II-173.
112. Castro PF, Greig D, Verdejo HE, Godoy I, Cordova S, Ferrada MP, Bourge RC. Intrapulmonary shunting associated with sildenafil treatment in a patient with idio-pathic pulmonary arterial hypertension. Thorax 2011;66 (12):1097-1098.
113. Vassalos A, Peng E, Young D, Walker S, Pollock J, Macarthur K, Lyall F, Danton MH. Pre-operative sildena-fil and pulmonary endothelial-related complications following cardiopulmonary bypass: a randomised trial in children undergoing cardiac surgery. Anaesthesia 2011;66 (6):472-480.
114. Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119(22):2894-2903.
115. Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. Pediatr Cardiol 2012;33(5):683-688.
116. Levinson AT, Klinger JR. Combination therapy for the treatment of pulmonary arterial hypertension. Ther Adv Respir Dis 2011;5(6):419-430.
117. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30(20):2493-2537.
118. Matamis D, Pampori S, Papathanasiou A, Papakonstanti-nou P, Tsagourias M, Galiatsou E, Koulouras V, Nakos G. Inhaled NO and sildenafil combination in cardiac surgery patients with out-of-proportion pulmonary hypertension: acute effects on postoperative gas exchange and hemody-namics. Circ Heart Fail 2012;5(1):47-53.
119. Fraisse A, Butrous G, Taylor MB, Oakes M, Dilleen M, Wessel DL. Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med 2011;37(3):502-509.
120. Hemmila MR, Napolitano LM. Severe respiratory failure: advanced treatment options. Crit Care Med 2006;34(9 suppl): S278-S290.
121. Nakamura H, Yamaguchi H, Amano A, Nakao T. Veno-venous extracorporeal membrane oxygenation is effective against post-cardiotomy acute respiratory failure in adults. Gen Thorac Cardiovasc Surg 2013.
122. Ravishankar C, Dominguez TE, Kreutzer J, Wernovsky G, Marino BS, Godinez R, Priestley MA, et al. Extracorporeal membrane oxygenation after stage I reconstruction for hy-poplastic left heart syndrome. Pediatr Crit Care Med 2006;7 (4):319-323.
123. Bhat P, Hirsch JC, Gelehrter S, Cooley E, Donohue J, King K, Gajarski RJ. Outcomes of infants weighing three kilograms or less requiring extracorporeal membrane oxygenation after cardiac surgery. Ann Thorac Surg 2013; 95(2):656-661.
124. Haines NM, Rycus PT, Zwischenberger JB, Bartlett RH, Undar A. Extracorporeal Life Support Registry Report 2008: neonatal and pediatric cardiac cases. ASAIO J 2009; 55(1):111-116.
125. Hartyanszky I, Szekely A, Kiraly L, Prodan Z, Mihalyi S, Bodor G, Tamas C, et al. Surgical management of congenital heart defects in adolescent and adult patients, between years 2001-2008. Orv Hetil 2009;150(37):1739-1743 [in Hungarian].
126. Undar A, McKenzie ED, McGarry MC, Owens WR, Surprise DL, Kilpack VD, Mueller MW, et al. Outcomes of congenital heart surgery patients after extracorporeal life support at Texas Children's Hospital. Artif Organs 2004; 28(10):963-966.
127. Slottosch I, Liakopoulos O, Kuhn E, Deppe AC, Scherner M, Madershahian N, Choi YH, Wahlers T. Outcomes after peripheral extracorporeal membrane oxygenation therapy for postcardiotomy cardiogenic shock: a single-center experience. J Surg Res 2012.
128. Schmid C, Philipp A, Hilker M, Rupprecht L, Arlt M, Keyser A, Lubnow M, Muller T. Venovenous extracorpo-real membrane oxygenation for acute lung failure in adults. J Heart Lung Transplant 2012;31(1):9-15.
129. Magovern GJ Jr., Simpson KA. Extracorporeal membrane oxygenation for adult cardiac support: the Allegheny experience. Ann Thorac Surg 1999;68(2):655-661.
130. Mishra V, Svennevig JL, Bugge JF, Andresen S, Mathisen A, Karlsen H, Khushi I, Hagen TP. Cost of extracorporeal membrane oxygenation: evidence from the Rikshospitalet University Hospital, Oslo, Norway. Eur J Cardiothorac Surg 2010;37(2):339-342.
131. Wu MY, Lin PJ, Lee MY, Tsai FC, Chu JJ, Chang YS, Haung YK, Liu KS. Using extracorporeal life support to resuscitate adult postcardiotomy cardiogenic shock: treatment strategies and predictors of short-term and midterm survival. Resuscitation 2010;81(9):1111-1116.
132. Gorenflo M, Gu H, Xu Z. Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congenital heart disease. Cardiology 2010;116(1):10-17.
133. Taylor MB, Laussen PC. Fundamentals of management of acute postoperative pulmonary hypertension. Pediatr Crit Care Med 2010;11(2 suppl):S27-S29.